FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2259278315> ?p ?o ?g. }

• W2259278315 endingPage "567" @default.
• W2259278315 startingPage "565" @default.
• W2259278315 abstract "Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment. In vitro, a synergy has been observed between this drug and ifosfamide (IFX). In addition, the pharmacokinetics of IFX suggest that it may have greater activity when given by continuous-intravenous infusion (c.i.v.i.). The aim of this study was, therefore, to assess the antitumor efficacy and toxicity of the combination of bolus VNR and c.i.v.i. IFX as second-line therapy in anthracycline-resistant breast cancer patients.Forty-two patients with MBC who had already received anthracycline-based chemotherapy were treated with a regimen consisting of IFX, by c.i.v.i. for 72 hours and bolus VNR. The courses were repeated every three weeks for a maximum of eight cycles. Four dose intensification steps were planned: IFX, 1.5 g/m2 on days 1-3 + VNR, 30 mg/m2 on day 1 (six patients); IFX, 2 g/m2 on days 1-3 + VNR, 25 mg/m2 on day 1 (six patients); IFX, 1.8 mg/m2 on days 1-3 + VNR, 25 mg/m2 on days 1 and 8 (six patients); IFX, 2 g/m2 on days 1-3 + VNR, 25 mg/m2 on days 1 and 8 (24 patients). Sodium-2-mercaptoethane sulfonate (mesna) was associated with IFX at an infusion ratio of 1:1 and, once the infusion was completed, per os every four hours for three times.All of the 42 patients entered were assessable for toxicity, and 41 of them for response. Neutropenia was the most frequently-occurring toxicity, but only five patients at the highest dose level (11.9%) presented grade 4, and none of those at the first three steps. Other significant toxic effects were mild (only grade I-II). The median relative dose intensity was 95% at the highest dose level and all of the treatments were administered on an out-patient basis. The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients). The median response duration was 7.0 months (range 2-13 months).The present phase I-II study shows that the IFX and VNR combination is an active and well-tolerated treatment in MBC and provides an alternative to taxanes for patients previously treated with anthracyclines." @default.
• W2259278315 created "2016-06-24" @default.
• W2259278315 creator A5012846994 @default.
• W2259278315 creator A5034404392 @default.
• W2259278315 creator A5040732392 @default.
• W2259278315 creator A5045496715 @default.
• W2259278315 creator A5058082424 @default.
• W2259278315 creator A5061726167 @default.
• W2259278315 creator A5080823945 @default.
• W2259278315 creator A5090814125 @default.
• W2259278315 date "1998-05-01" @default.
• W2259278315 modified "2023-10-03" @default.
• W2259278315 title "Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I–II clinical trial" @default.
• W2259278315 cites W178142031 @default.
• W2259278315 cites W2020496608 @default.
• W2259278315 cites W2030726570 @default.
• W2259278315 cites W2081718040 @default.
• W2259278315 cites W2085689060 @default.
• W2259278315 cites W2199860498 @default.
• W2259278315 cites W2335387739 @default.
• W2259278315 cites W2424234170 @default.
• W2259278315 doi "https://doi.org/10.1023/a:1008221109364" @default.
• W2259278315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9653499" @default.
• W2259278315 hasPublicationYear "1998" @default.
• W2259278315 type Work @default.
• W2259278315 sameAs 2259278315 @default.
• W2259278315 citedByCount "11" @default.
• W2259278315 crossrefType "journal-article" @default.
• W2259278315 hasAuthorship W2259278315A5012846994 @default.
• W2259278315 hasAuthorship W2259278315A5034404392 @default.
• W2259278315 hasAuthorship W2259278315A5040732392 @default.
• W2259278315 hasAuthorship W2259278315A5045496715 @default.
• W2259278315 hasAuthorship W2259278315A5058082424 @default.
• W2259278315 hasAuthorship W2259278315A5061726167 @default.
• W2259278315 hasAuthorship W2259278315A5080823945 @default.
• W2259278315 hasAuthorship W2259278315A5090814125 @default.
• W2259278315 hasBestOaLocation W22592783151 @default.
• W2259278315 hasConcept C112705442 @default.
• W2259278315 hasConcept C121608353 @default.
• W2259278315 hasConcept C126322002 @default.
• W2259278315 hasConcept C141071460 @default.
• W2259278315 hasConcept C2775930923 @default.
• W2259278315 hasConcept C2776694085 @default.
• W2259278315 hasConcept C2776802502 @default.
• W2259278315 hasConcept C2777506904 @default.
• W2259278315 hasConcept C2777511904 @default.
• W2259278315 hasConcept C2778119113 @default.
• W2259278315 hasConcept C2778239845 @default.
• W2259278315 hasConcept C2780350996 @default.
• W2259278315 hasConcept C2780376820 @default.
• W2259278315 hasConcept C2781413609 @default.
• W2259278315 hasConcept C31760486 @default.
• W2259278315 hasConcept C42219234 @default.
• W2259278315 hasConcept C43376680 @default.
• W2259278315 hasConcept C530470458 @default.
• W2259278315 hasConcept C71924100 @default.
• W2259278315 hasConcept C90924648 @default.
• W2259278315 hasConceptScore W2259278315C112705442 @default.
• W2259278315 hasConceptScore W2259278315C121608353 @default.
• W2259278315 hasConceptScore W2259278315C126322002 @default.
• W2259278315 hasConceptScore W2259278315C141071460 @default.
• W2259278315 hasConceptScore W2259278315C2775930923 @default.
• W2259278315 hasConceptScore W2259278315C2776694085 @default.
• W2259278315 hasConceptScore W2259278315C2776802502 @default.
• W2259278315 hasConceptScore W2259278315C2777506904 @default.
• W2259278315 hasConceptScore W2259278315C2777511904 @default.
• W2259278315 hasConceptScore W2259278315C2778119113 @default.
• W2259278315 hasConceptScore W2259278315C2778239845 @default.
• W2259278315 hasConceptScore W2259278315C2780350996 @default.
• W2259278315 hasConceptScore W2259278315C2780376820 @default.
• W2259278315 hasConceptScore W2259278315C2781413609 @default.
• W2259278315 hasConceptScore W2259278315C31760486 @default.
• W2259278315 hasConceptScore W2259278315C42219234 @default.
• W2259278315 hasConceptScore W2259278315C43376680 @default.
• W2259278315 hasConceptScore W2259278315C530470458 @default.
• W2259278315 hasConceptScore W2259278315C71924100 @default.
• W2259278315 hasConceptScore W2259278315C90924648 @default.
• W2259278315 hasIssue "5" @default.
• W2259278315 hasLocation W22592783151 @default.
• W2259278315 hasLocation W22592783152 @default.
• W2259278315 hasOpenAccess W2259278315 @default.
• W2259278315 hasPrimaryLocation W22592783151 @default.
• W2259278315 hasRelatedWork W1969867024 @default.
• W2259278315 hasRelatedWork W2015663508 @default.
• W2259278315 hasRelatedWork W202706044 @default.
• W2259278315 hasRelatedWork W2079713072 @default.
• W2259278315 hasRelatedWork W2087025815 @default.
• W2259278315 hasRelatedWork W2136276647 @default.
• W2259278315 hasRelatedWork W2259278315 @default.
• W2259278315 hasRelatedWork W2286570434 @default.
• W2259278315 hasRelatedWork W2729287692 @default.
• W2259278315 hasRelatedWork W3032730637 @default.
• W2259278315 hasVolume "9" @default.
• W2259278315 isParatext "false" @default.
• W2259278315 isRetracted "false" @default.
• W2259278315 magId "2259278315" @default.
• W2259278315 workType "article" @default.